Progyny (PGNY) Cost of Revenue (2018 - 2026)

Progyny (PGNY) has reported Cost of Revenue for 9 consecutive years, with $261.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 2.88% year-over-year to $261.2 million in Q2 2026; TTM through Jun 2026 was $988.7 million, a 2.5% increase from a year earlier, with the FY2025 full-year figure at $984.2 million, up 7.69% from the prior year.
• Cost of Revenue was $261.2 million for Q2 2026 at Progyny, up from $245.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $261.2 million in Q2 2026 and troughed at $139.3 million in Q1 2022.
• A 5-year average of $215.2 million and a median of $223.1 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 69.92% in 2022 and dropped 1.13% in 2026, its largest moves.
• Over 5 years, Cost of Revenue stood at $169.8 million in 2022, then grew by 25.45% to $213.0 million in 2023, then increased by 10.3% to $235.0 million in 2024, then rose by 2.78% to $241.5 million in 2025, then increased by 8.15% to $261.2 million in 2026.
• The last three Cost of Revenue figures came in at $261.2 million (Q2 2026), $245.4 million (Q1 2026), and $241.5 million (Q4 2025), per Business Quant data.